Management of Nephrocalcinosis in Adults

Diagnostic Workup and Initial Management

The American College of Physicians recommends obtaining serum calcium, phosphate, creatinine, intact PTH, and 25-OH vitamin D levels to evaluate for primary hyperparathyroidism, renal tubular acidosis, and vitamin D disorders 1, 2
The National Kidney Foundation suggests measuring spot urine calcium/creatinine ratio to assess for hypercalciuria, the most common risk factor 1
The European Renal Association recommends checking serum alkaline phosphatase to evaluate for bone disease 3
The American Society of Nephrology advises performing renal ultrasonography to confirm nephrocalcinosis extent and distribution 1

The American College of Cardiology recommends increasing fluid intake aggressively to achieve urine output >2.5 liters daily to reduce urinary supersaturation 1, 2
The National Institute of Diabetes and Digestive and Kidney Diseases suggests limiting sodium intake to <100 mEq/day to reduce urinary calcium excretion 3, 1
The Endocrine Society recommends implementing moderate calcium restriction (400-800 mg/day) only if hypercalciuria is documented, as excessive restriction can worsen bone disease 3, 1

The American Society of Nephrology recommends administering potassium citrate to increase urinary citrate (a crystallization inhibitor) and raise urinary pH 4, 2
The National Kidney Foundation advises avoiding sodium citrate, as it increases urinary calcium excretion 2

The European Renal Association recommends monitoring serum calcium, phosphate, creatinine, and PTH every 2-4 months initially, then adjust frequency based on stability 3, 1
The American Society of Nephrology suggests performing renal ultrasonography yearly in patients with established nephrocalcinosis to assess progression 3, 1

The American College of Medical Genetics recommends keeping urinary calcium excretion within normal range by adjusting active vitamin D dosing in patients with X-linked hypophosphatemia 6, 4, 5
The Endocrine Society advises avoiding large doses of phosphate supplements (>80 mg/kg daily) in patients with X-linked hypophosphatemia 4
The National Institute of Diabetes and Digestive and Kidney Diseases recommends considering switching to burosumab if nephrocalcinosis develops or worsens on conventional therapy 3

The American Society of Nephrology recommends referring to nephrology for progressive nephrocalcinosis despite initial management, eGFR <60 mL/min/1.73 m² or declining renal function, and complex metabolic disorders requiring specialized management 1
The Endocrine Society suggests referring to endocrinology for primary hyperparathyroidism requiring surgical evaluation, suspected genetic hypophosphatemic disorders, and vitamin D metabolism disorders 1, 2, 3